Bruker Corporation $BRKR Shares Sold by Amundi

Key Points

• Amundi cut its Bruker stake by 79.4% in the second quarter, selling 49,707 shares and retaining 12,904 shares valued at approximately $777,000. Institutional investors and hedge funds collectively own 79.52% of the company.
• Analyst sentiment is mixed: Bruker has a consensus rating of “Hold” and an average price target of $57, while several firms recently raised their targets to between $60 and $70.
• Bruker reported quarterly EPS of $0.49, beating estimates of $0.38, while revenue rose 5.2% year over year to $838.5 million. The company also declared a quarterly dividend of $0.05 per share, representing a 0.4% yield.

Amundi decreased its stake in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 79.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,904 shares of the medical research company's stock after selling 49,707 shares during the period. Amundi's holdings in Bruker were worth $777,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Bruker in the 2nd quarter valued at $1,456,000. HB Wealth Management LLC acquired a new stake in shares of Bruker during the 2nd quarter worth $352,000. Nykredit A S acquired a new stake in shares of Bruker during the 2nd quarter worth $207,000. Alyeska Investment Group L.P. raised its position in shares of Bruker by 86.2% in the 2nd quarter. Alyeska Investment Group L.P. now owns 1,410,164 shares of the medical research company's stock worth $84,864,000 after buying an additional 653,007 shares during the period. Finally, Ferguson Wellman Capital Management Inc. purchased a new position in shares of Bruker in the 2nd quarter worth $251,000. 79.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Bruker in a research report on Monday, August 31st. Leerink Partners boosted their price objective on shares of Bruker from $60.00 to $70.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 7th. Guggenheim increased their price objective on shares of Bruker from $50.00 to $70.00 and gave the stock a "buy" rating in a research report on Monday, June 29th. Barclays upped their target price on Bruker from $53.00 to $60.00 and gave the stock an "overweight" rating in a research report on Wednesday, June 24th. Finally, Stifel Nicolaus set a $50.00 target price on Bruker in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Bruker has a consensus rating of "Hold" and an average price target of $57.00.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $55.75 on Wednesday. Bruker Corporation has a twelve month low of $30.09 and a twelve month high of $65.30. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $8.49 billion, a price-to-earnings ratio of -79.64, a price-to-earnings-growth ratio of 1.61 and a beta of 1.26. The business has a 50 day simple moving average of $58.02 and a 200-day simple moving average of $49.52.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The firm had revenue of $838.50 million for the quarter, compared to analysts' expectations of $853.57 million. During the same period last year, the business posted $0.32 earnings per share. The firm's revenue for the quarter was up 5.2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities research analysts expect that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Monday, September 21st will be issued a $0.05 dividend. The ex-dividend date of this dividend is Monday, September 21st. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Bruker's dividend payout ratio (DPR) is -28.57%.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company's product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.